Millennium Management LLC Cuts Position in SOPHiA GENETICS SA (NASDAQ:SOPH)

Millennium Management LLC trimmed its holdings in SOPHiA GENETICS SA (NASDAQ:SOPH) by 63.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 662,656 shares of the company’s stock after selling 1,158,816 shares during the period. Millennium Management LLC’s holdings in SOPHiA GENETICS were worth $3,035,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. grew its holdings in SOPHiA GENETICS by 35.9% in the 2nd quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock valued at $6,267,000 after buying an additional 361,201 shares during the last quarter. Akre Capital Management LLC bought a new position in SOPHiA GENETICS during the first quarter worth about $1,418,000. Essex Investment Management Co. LLC raised its holdings in SOPHiA GENETICS by 112.1% during the first quarter. Essex Investment Management Co. LLC now owns 262,834 shares of the company’s stock worth $1,296,000 after acquiring an additional 138,933 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in SOPHiA GENETICS by 5.0% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 203,334 shares of the company’s stock worth $1,002,000 after buying an additional 9,700 shares during the last quarter. Finally, Moloney Securities Asset Management LLC grew its position in shares of SOPHiA GENETICS by 111.4% in the first quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after purchasing an additional 93,800 shares during the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Trading Down 3.6 %

Shares of SOPHiA GENETICS stock opened at $3.39 on Tuesday. The company has a fifty day simple moving average of $3.67 and a 200-day simple moving average of $4.40. SOPHiA GENETICS SA has a 12-month low of $2.70 and a 12-month high of $7.37. The stock has a market cap of $221.29 million, a price-to-earnings ratio of -3.02 and a beta of 1.03. The company has a current ratio of 4.40, a quick ratio of 4.17 and a debt-to-equity ratio of 0.11.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm had revenue of $15.81 million for the quarter, compared to analyst estimates of $17.58 million. SOPHiA GENETICS had a negative net margin of 102.84% and a negative return on equity of 47.40%. During the same quarter last year, the firm posted ($0.33) earnings per share. On average, equities analysts forecast that SOPHiA GENETICS SA will post -0.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SOPH shares. Morgan Stanley downgraded SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $10.00 to $5.00 in a report on Wednesday, August 7th. Royal Bank of Canada cut their price target on shares of SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Finally, Guggenheim started coverage on shares of SOPHiA GENETICS in a research report on Thursday, June 27th. They set a “buy” rating and a $6.00 price target for the company.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.